zurich, switzerland, october 27, 2014 &ndash haselmeier announces that biocon, one of asia&rsquos premier biotechnology companies, has just launched insupen® ez in india. the insupen® ez is a second generation pen and follows on the success s of biocon&rsquos premier insulin delivery device insupen®. under the terms of the agreement between the two companies, biocon has worldwide distribution rights to insupen® ez, for use with biocon&rsquos insulin, basalog&trade and insugen&trade, and insulin analogues.the insupen® ez is a reusable insulin pen, based on haselmeier&rsquos new ipen² platform and is designed to be easy to use and provide a smoother injection experience. it can deliver insulin doses from 1 unit 0.01 ml to 60 units 0.60 ml in increments of 1 unit 0.01 ml with insulin preparations of 100 iuml and features an audible sound when dialling a dose for accurate and reliable dosing. the insupen® ez is available in an egg shell white thermoresistant, lightweight terluran body and is available in different colours for differentiating insulins.the launch of insupen® ez, represents another milestone in the longstanding relationship between biocon and haselmeier. &ldquohaselmeier is delighted to collaborate with biocon and contribute to the market introduction of insupen® ez&rdquo, says sandra de haan, director project management at haselmeier gmbh.about haselmeierfounded in stuttgart in 1920, haselmeier is one of the leading designers and manufacturers of injection systems. haselmeier&rsquos devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. at five locations on three continents, haselmeier develops and produces innovative technology for drug delivery which enhances the health and daily life of the patient. please find further information under www.haselmeier.comabout bioconestablished in 1978, biocon limited bse code 532523, nse id biocon, isin id ine376g01013 is india&39s largest biotechnology company by revenue. the group, promoted by ms. kiran mazumdarshaw, is a fullyintegrated, innovationdriven healthcare enterprise with strategic focus on biopharmaceuticals and research services. biocon&rsquos value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. with successful initiatives in clinical development, bioprocessing and global marketing, biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. many of these products have usfda and ema acceptance. biocon&rsquos robust product offering includes the world&rsquos first pichiabased recombinant human insulin, insugen® and india&rsquos first indigenously produced monoclonal antibody biomabegfrtm.www.biocon.com
